September 2024 – Page 13

Soy Protein Ingredients Market Growth, Emerging Trends, Size, Share, Business Opportunities, Industry Analysis, Key Segments, Leading Players, and Forecast – 2027

“MarketsandMarkets™”

Soy Protein Ingredients Market by Type (Soy Protein Concentrates, Soy Protein Isolates, Textured Soy Protein, and Soy Flours), Application (Food and Feed), Form (Dry and Liquid), Nature, Function, and Region – Global Forecast to 2027

The soy protein ingredients industry was valued at USD 7.7 billion in 2022 and is projected to reach USD 10.8 billion by 2027, reflecting a compound annual growth rate (CAGR) of 7.0% during the forecast period from 2022 to 2027. Soy protein ingredients are produced by processing soymeal to obtain products with elevated protein levels, making them ideal for diverse applications in food and animal feed. The rising demand for soy protein in these sectors is driven by its health advantages, versatile functional properties, and cost-effectiveness as an alternative to animal protein. As a result, this market is anticipated to grow at a much faster rate than other vegetable protein sources.

Soy Protein Ingredients Market

Soy Protein Ingredients Market Trends:

Increasing Demand for Plant-Based Protein: Consumers are showing a rising interest in plant-based alternatives to animal products, driven by factors such as health awareness, environmental sustainability, and concerns over animal welfare. Soy protein stands out as a versatile, cost-effective plant-based option that can be incorporated into a wide variety of food and beverage products.

Heightened Health and Wellness Awareness: As consumers become more conscious of the role protein plays in maintaining good health, soy protein emerges as a valuable source of essential amino acids. Research has linked soy protein to several health benefits, including a reduced risk of heart disease, stroke, and certain cancers.

Rapid Expansion of the Asia Pacific Market: The Asia Pacific region is projected to be the fastest-growing market for soy protein ingredients in the coming years. This growth is fueled by factors like rising disposable incomes, increased urbanization, and heightened awareness of soy protein’s health benefits.

Innovative Product Development: Food and beverage manufacturers are continuously developing new products that incorporate soy protein ingredients. This innovation is expanding the range of options available to consumers, including plant-based meat substitutes, dairy alternatives, and protein-enriched snacks.

Emphasis on Non-GMO and Organic Ingredients: There’s a growing preference for non-GMO and organic soy protein ingredients among consumers, driven by concerns about the safety of genetically modified organisms (GMOs) and the environmental impact of conventional farming practices.

Soy Protein Ingredients Market Drivers: Demand for cheaper protein source

The expansion of crop cultivation in developing regions like South America and Asia Pacific, combined with existing global practices, has led to a greater availability of soy proteins. As a result, raw materials are easily sourced from contract farmers or oilseed crushers supplying soy meal. The low processing costs associated with soy protein align well with the operational needs of manufacturers, enabling them to invest more effectively in product development. Consequently, soy proteins are more cost-effective compared to other protein sources such as meat, dairy, and whey. Furthermore, with the recent rise in prices of conventional dairy products, soy protein stands out as a highly competitive alternative in terms of affordability.

North America is estimated to dominate the soy protein ingredients market share.

The ethical limitations and consumer awareness regarding personal and environmental health have contributed greatly to the mass shifting of people toward adopting veganism and flexitarian diets. According to a recent report published in March 2022 by the Plant-Based Foods Association (PBFA), the US plant-based food retail sales reached USD 7.4 billion, outpacing total food retail sales and showing a growth rate of 6.1% in 2021 from the previous year, despite supply chain interruptions and pandemic restrictions. This growth and increase in the demand for and consumption of plant-based foods are likely to continue during the forecast period and present significant business opportunities for soy protein ingredients.

North America is a significant production base for plant-based protein manufacturers, and the US is a key producer of soybean and wheat in the region.

Top Soy Protein Ingredients Companies:

The key players in this market include ADM (US), Wilmar International Co., Ltd. (Singapore), Cargill, Incorporated (US), CHS, Inc. (US), and Fuji Oil Holdings Inc (Japan).

Key Questions Addressed by the Soy Protein Ingredients Market Report:

What are soy protein ingredients?

What are the primary applications of soy protein ingredients?

What are the health benefits of soy protein?

How is the soy protein ingredients market expected to grow in the coming years?

What factors are driving the demand for soy protein ingredients?

What are the challenges faced by the soy protein ingredients market?

Who are the major players in the soy protein ingredients market?

What regions are the largest markets for soy protein ingredients?

What trends are currently shaping the soy protein ingredients market?

How big is the soy protein ingredients market?

What is the estimated growth rate of soy protein ingredients market?

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/soy-protein-ingredients-market-857.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soy Protein Ingredients Market Growth, Emerging Trends, Size, Share, Business Opportunities, Industry Analysis, Key Segments, Leading Players, and Forecast – 2027

Giftshire Presents Special Christmas Gifts Collection to Let Everyone Reveal their Favorite K-Drama Characters

Giftshire’s Christmas collection offers an extensive selection of personalized gifts, from laser-engraved glasses to customizable mugs and stockings.

This holiday season, Giftshire invites everyone to make Christmas unforgettable with its one-of-a-kind, personalized gift collection. The store is celebrating the magic of the season by giving gifts that reflect not only the spirit of Christmas but also the charm and sentimentality of favorite K-Drama characters. Giftshire proudly presents a wide variety of custom gifts under $25, ensuring there’s something special for everyone.

Giftshire’s Christmas collection offers an extensive selection of personalized gifts, from laser-engraved glasses to customizable mugs, ensuring that festive presents are as unique as the moments shared with loved ones. In addition to festive decor, kitchen utilities, perfumes, and baby bags, buyers will find holiday favorites like Christmas ornaments and stockings made just for the season.

Personalized stockings at Giftshire with seven festive characters: https://www.giftshire.com/products/personalized-christmas-stockings-featuring-7-festive-characters

For those looking to add a personal touch to their Christmas tree, Giftshire’s personalized ornaments are a perfect choice. Options include custom photo ornaments or engraved wooden decorations, bringing a touch of magic and individuality to the holidays. Make this Christmas extra special with the perfect blend of sentimentality and style.

Among Giftshire’s standout items is the bestselling Engraved Wood Pocket Knife—an ideal gift for the outdoor enthusiast in your life. This personalized knife, which can be customized with a name and date of your choice, combines practicality and elegance. It’s a gift that’s sure to be cherished for years to come.

For holiday decor, Giftshire also offers beautifully embroidered Christmas stockings, such as the Personalized Christmas Velvet Stocking, where one can add a name to transform a simple stocking into a lasting keepsake.

To elevate the gift-giving experience, Giftshire provides elegant packaging options, including classy gift boxes that enhance the presentation of personalized presents. Every detail is carefully considered to ensure that both the gift and its packaging stand out as a true expression of thoughtfulness.

To help customers during the bustling holiday season, Giftshire shares three simple tips to make Christmas shopping easier:

1. Set a budget based on how much to spend for each recipient.

2. Check for discounts and exclusive deals to snag great gifts at lower prices.

3. Opt for customized gifts that will bring a smile to loved ones’ faces.

Giftshire offers a secure shopping experience with safe payment methods, glowing customer reviews, and a strong return policy. Whether shopping for a K-Drama fan or simply looking for something special, Giftshire is the ultimate destination for personalized Christmas gifts this season.

About Giftshire

Giftshire is an online destination for personalized and custom gifts. With a focus on affordability, quality, and sentimentality, Giftshire helps you create meaningful gifts for every occasion. Explore their wide range of products and bring a personal touch to holiday celebrations.

Social media:

https://www.facebook.com/profile.php?id=100095424698665

https://www.instagram.com/gift.shire/

Media Contact
Company Name: Giftshire Inc
Contact Person: Özkurt Cihan Yildiz
Email: Send Email
Phone: +1 (909) 529-0347
Address:1649 E Miraloma Ave
City: Placentia
State: CA, 92870
Country: United States
Website: https://www.giftshire.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Giftshire Presents Special Christmas Gifts Collection to Let Everyone Reveal their Favorite K-Drama Characters

Agricultural Biologicals Market Growth, Emerging Trends, Size, Share, Business Opportunities, Industry Analysis, Key Segments, Leading Players, and Forecast – 2029

“MarketsandMarkets™”

Agricultural Biologicals Market by Type (Biocontrol, Biostimulants, Biofertilizers), Source (Microbials, Macrobials, Semiochemicals, Natural Products), Mode of Application (Foliar Spray, Seed Treatment, Soil Treatment)—Global Forecast to 2029

The agricultural biologicals market size is expected to grow from USD 16.7 billion in 2024 to USD 31.8 billion by 2029, with a compound annual growth rate (CAGR) of 13.8% during this period. The growing demand for agricultural biologicals is largely fueled by the increasing challenges faced in conventional farming, such as diseases, pests, and soil degradation. Moreover, global regulations and government initiatives are encouraging a shift towards more sustainable agricultural practices instead of relying on chemical inputs. In India, programs like the Pradhan Mantri Krishi Sinchai Yojana (PMKSY) and the National Mission on Sustainable Agriculture (NMSA) are spearheading these efforts. The NMSA emphasizes the use of non-toxic biofertilizers and biopesticides to improve soil health and crop productivity. Meanwhile, PMKSY, which primarily aims to enhance irrigation, also incorporates sustainable technologies, including agricultural biologicals, to improve soil fertility and resilience, supporting the overall goals of sustainable agriculture.

Agricultural Biologicals Market

Agricultural Biologicals Market Drivers:

The Agricultural Biologicals Market is influenced by several key drivers:

Sustainable Farming Practices: Growing demand for environmentally friendly farming practices is pushing the adoption of agricultural biologicals. These products, such as biopesticides and biofertilizers, offer a more sustainable alternative to chemical inputs.

Regulatory Support: Increasing regulations and restrictions on chemical pesticides and fertilizers are encouraging farmers to seek out biological alternatives. Governments and regulatory bodies are providing support and incentives for the use of biological products.

Consumer Demand: Rising consumer preference for organic and non-GMO products is driving the market for agricultural biologicals. Consumers are increasingly aware of the benefits of using products that are less harmful to the environment and human health.

Advancements in Technology: Innovations in biotechnology and microbiology are leading to the development of more effective and targeted biological products. Research and development in this field are enhancing the efficacy and application of agricultural biologicals.

Climate Change: Changing climate conditions are impacting crop yields and pest patterns, creating a need for new solutions to manage these challenges. Agricultural biologicals can offer adaptive solutions for pest and disease management in varying climates.

Soil Health and Fertility: There’s a growing recognition of the importance of maintaining soil health and fertility. Biological products, such as mycorrhizal fungi and plant growth-promoting rhizobacteria (PGPR), are increasingly used to enhance soil quality and nutrient availability.

Economic Benefits: Biological products can often be cost-effective in the long term by reducing the need for chemical inputs and improving crop yields. This economic advantage is a significant driver for adoption among farmers.

Integration with Conventional Practices: The ability to integrate biological products with conventional agricultural practices allows farmers to benefit from both approaches. This integration helps in managing pests and diseases while optimizing crop production.

Agricultural Biologicals Market Opportunities: advancements in microbial research undertaken by key players

Advancements in microbiology research are opening new opportunities in the agricultural biologicals market. Leading companies and institutions are making significant investments in discovering and developing more effective microbial strains for plants and soil, while also enhancing pest and disease control methods. Innovations in biotechnology, genomics, and fermentation are boosting the production of more potent biological products. For example, the use of AI and big data analytics in microbial research is speeding up the identification and optimization of key agricultural microbes. These breakthroughs are driving the creation of next-generation biologicals with improved effectiveness, quicker action, and wider applications, expanding the market.

Fruits and vegetables are projected to experience the highest CAGR in the crop type segment throughout the forecast period.

Farmers are turning to agri-biologicals more than ever to protect their crops, as even small damage can result in significant financial losses. Fruits and vegetables, due to their fast growth cycles, demand more frequent and accurate protection from pests and diseases, which agri-biologicals effectively deliver. Their high perishability and strict quality standards, especially for export markets, are key factors driving the use of biological products that leave no harmful residues while ensuring safety and quality. Furthermore, the intensive cultivation methods used in fruit and vegetable farming increase the need for reliable biological solutions to maintain both yield and quality.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100393324

The agricultural biologicals market in the North American region is expected to grow at the highest CAGR during the forecast period.

The growth of this market is being driven by key industry players and the frequent introduction of innovative biological products tailored for local agricultural applications. Additionally, North America’s well-established regulatory frameworks facilitate quicker approval and adoption of these new products. The emphasis on large-scale commercial farming in the region, which prioritizes higher yields with minimal resistance to pests and diseases, further fuels the demand for advanced agricultural biologicals. Consequently, this trend is enhancing the market, supported by the increased use of precision agriculture technologies that improve the application and effectiveness of biologicals in North America.

Top Agricultural Biologicals Companies:

The key players in the agricultural biologicals market include BASF SE (Germany), Syngenta Group (Switzerland), Bayer AG (Germany), FMC Corporation (US), Corteva (US), UPL (India), Nufarm (Australia), Novozymes A/S (Denmark), Lallemand Inc (Canada), Mosaic (US), Rovensa Next (Spain), Sumitomo Chemical Co., Ltd (Japan), SEIPASA, S.A. (Spain), Koppert (Netherlands), and Gowan Company (US). These market participants are emphasizing the expansion of their footprint via agreements and partnerships. They maintain a robust presence in North America, Asia Pacific, South America, RoW, and Europe, and they are supported by manufacturing facilities and well-established distribution networks spanning these regions.

Agricultural Biologicals Industry News:

In May 2024, Bioceres Crop Solutions Corp. announced that the Ministry of Agriculture and Livestock from Brazil, MAPA-Ministério de Agricultura e Pecuária, had approved three new bio-insecticidal and bio-nematocidal solutions derived from inactivated cells of the company’s proprietary Burkholderia platform.

In January 2024, Certis Biologicals introduced Convergence Biofungicide, a new, powerful crop protection solution for corn, soybeans, and peanuts. This innovation from Certis Biologicals brings to row crop farmers the best combination of top disease control and more plant health in one convenient, lower-priced package.

In December 2023, Biobest Group NV introduced a new plant defense elicitor, FytoSol, designed to offer preventative protection against tomato leaf mold caused by Cladosporium (Passalora fulva) in Morocco.

Schedule a call with our analysts to discuss your business needs: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=100393324

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Agricultural Biologicals Market Growth, Emerging Trends, Size, Share, Business Opportunities, Industry Analysis, Key Segments, Leading Players, and Forecast – 2029

Niemann-Pick Disease Type C Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Niemann-Pick Disease Type C Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Niemann-Pick Disease Type C Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Niemann-Pick Disease Type C Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Niemann-Pick Disease Type C, historical and forecasted epidemiology as well as the Niemann-Pick Disease Type C market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Niemann-Pick Disease Type C Market by downloading the comprehensive report from DelveInsight @ Niemann-Pick Disease Type C Treatment Market Size

Key Takeaways from the Niemann-Pick Disease Type C Market Report

As per the analysis conducted by DelveInsight, in 2023, the total diagnosed prevalent cases of Niemann Pick Disease Type C were 789 cases in the 7MM and these cases are further projected to increase in the forecasted period of (2023-2034)
As per DelveInsight’s analysts, there were 37 diagnosed prevalent cases of NPC in the juvenile (6 to < 15 years) type in Japan in 2023.
The diagnosed prevalent cases of NPC in the 7MM varied according to gender, with diagnosed prevalent cases higher in females than males. Assessments as per DelveInsight’s analysts show that the overall diagnosed prevalent rate of NPC (in the 7MM) in females were 65%, while it was 45% in males in 2023.
In 2023, EU4 countries and the UK accounted for 329 cases. Of all the four major European countries, Germany recorded the highest diagnosed Diagnosed Prevalent cases of NPC, with 84 cases in 2023, making up 26% of the total four European countries, and they are expected to increase during the study period (2020–2034).
In 2023, Spain reported the fewest prevalent cases of NPC among EU4 countries, with a total of 47 diagnoses. This low figure highlights Spain’s relatively lower incidence of this rare genetic disorder compared to its EU4 counterparts. Such data may reflect both effective disease management and possibly lower prevalence rates in the region.
The leading Niemann-Pick Disease Type C Companies such as Mandos Health, Cycle Therapeutics, Intra Bio, Zevra Therapeutics, and others.
Promising Niemann-Pick Disease Type C Therapies such as Arimoclomol, AZ-3102, IB1001 (N-acetyl-L-leucine), and others.

Gain a competitive edge in the Niemann-Pick Disease Type C Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Niemann-Pick Disease Type C Treatment Drugs

Niemann-Pick Disease Type C Epidemiology Segmentation in the 7MM

Total Niemann-Pick Disease Type C Diagnosed Prevalent cases
Niemann-Pick Disease Type C Gender- specific Diagnosed prevalent Cases
Niemann-Pick Disease Type C Distribution of diagnosed Prevalent Cases

Niemann-Pick Disease Type C Treatment Market

Treatment of NPC may require the coordinated efforts of a team of specialists. Pediatricians, neurologists, ophthalmologists, pulmonologists, gastroenterologists, and other healthcare professionals may need to systematically and comprehensively plan an affected child’s treatment. Psychosocial support for the entire family is essential as well. Genetic counseling would benefit affected individuals and their families. Current treatment is directed toward the specific symptoms apparent in each individual. Difficulty swallowing (dysphagia) should be monitored and evaluated regularly for the risk of aspiration. Swallowing difficulties may first be managed by softening solids and thickening liquids. A speech therapist can work with the individual to optimize swallowing function. Eventually, a gastronomy tube may be required to meet adequate caloric needs. With this procedure, a thin tube is placed into the stomach via a small incision in the abdomen, allowing for the direct intake of food or medicine.

Discover key developments and opportunities in the Niemann-Pick Disease Type C Market. Click here to learn more from DelveInsight’s latest report @ Niemann-Pick Disease Type C Market Size

Niemann-Pick Disease Type C Market Insights

Niemann–Pick Disease Type C can be treated by using disease-specific therapies, and symptomatic therapies are recommended for treating neurological, visceral, and psychiatric manifestations associated with Niemann–Pick Disease Type C. The emergence of innovative treatments such as therapeutic vaccines and helicase-primase inhibitors offers hopeful prospects for addressing NPC infections. These developments signify a shift towards more targeted and potentially more effective treatments, offering renewed hope for individuals affected by NPC infections.

Niemann-Pick Disease Type C Emerging Therapies and Companies

Arimoclomol: Zevra Therapeutics
AZ-3102: Azafaros A.G.
IB1001 (N-acetyl-L-leucine): IntraBio

Download DelveInsight’s Niemann-Pick Disease Type C Market report today and stay ahead in this rapidly evolving field. @ Niemann-Pick Disease Type C Clinical Trials

Scope of the Niemann-Pick Disease Type C Market Report

Coverage- 7MM
Niemann-Pick Disease Type C Companies- Mandos Health, Cycle Therapeutics, Intra Bio, Zevra Therapeutics, and others.
Niemann-Pick Disease Type C Therapies- Arimoclomol, AZ-3102, IB1001 (N-acetyl-L-leucine), and others.
Niemann-Pick Disease Type C Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Niemann-Pick Disease Type C Unmet Needs, KOL’s views, Analyst’s views, Niemann-Pick Disease Type C Market Access and Reimbursement

Download the report to understand which factors are driving Niemann-Pick Disease Type C Market Trends @ Niemann-Pick Disease Type C Market Trends

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Niemann-Pick Disease Type C Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Treatment Algorithm

9. Japan

10. Patient Journey

11. Marketed Drugs

12. Emerging Therapies

13. Niemann-Pick Disease Type C: Seven Major Market Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Niemann-Pick Disease Type C Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Gluten-Free Products Market Projected to Reach $11.48 Billion by 2029 | Key Players are The Kraft Heinz Company, The Hain Celestial Group, General Mills Inc., Conagra Brands, Inc., and Genius Food

“MarketsandMarkets™”

Gluten-free Products Market by Type (Bakery Products, Snacks & RTE Products, Pizzas & Pastas, Condiments & Dressings), Form, Distribution Channel (Conventional Stores, Specialty Stores, and Drugstores & Pharmacies), Source – Global Forecast to 2029

The global gluten-free products market, estimated to be USD 7.70 billion in 2024, showcases a remarkable growth projection, anticipated to escalate to USD 11.48 billion by 2029, indicating a robust compound annual growth rate (CAGR) of 8.3% during the forecast period. In addition to celiac disease, there are other driving elements contributing to the recent growth of the gluten-free market. Most consumers turn to gluten-free diets because of perceived health benefits such as improved digestion and increased energy levels. This is further fueled by rising awareness of gluten sensitivity and its potential impact on overall wellness. Moreover, it is the pursuit of a healthy lifestyle and eating habits that health-conscious and fitness-oriented people prefer. This leads to further curiosity regarding gluten-free products. Examples include the introductions of The Kraft Heinz Company (US) with Fudge n’ Vanilla French Fry Pop and The Hain Celestial Group with Garden Veggie Flavor Burst Tortilla Chips in 2024. The Fudge n’ Vanilla French Fry Pop combines vanilla oat milk with a chocolate fudge shell, while the Flavor Burst Tortilla Chips contain vegetable-based flavors. Both products cater to rising consumer interest in new, allergen-friendly, healthier products that continue to fuel the growth of the gluten-free market.

Gluten-free Products Market

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=738

The specialty stores category within the gluten-free products by distribution channels segment maintains a significant position throughout the forecast period.

Specialty stores like bakery stores, gourmet stores, and confectionery stores hold a significant share in the gluten-free products market because their offerings are specialized and well-complemented by personalized customer service. Bakery stores are in demand due to the variety in fresh, gluten-free baked items they are able to provide, meeting local taste preferences and individual nutritional requirements. Gourmet stores appeal to health-oriented consumers and often carry a hand-selected line of high-quality gluten-free products that may include specialty or gourmet items. The confectionery outlets also sell gluten-free sweets and other indulgence products that the sweet-tooth-craving individual with an allergy may desire. For instance, Whole Foods Market has introduced a wide range of gluten-free product offerings and, by doing so, strengthened its market position and established itself as a reliable source for gluten-free customers. Specialized channels meet particular consumer needs and serve to make the market more accessible.

The pizzas & pastas category within the gluten-free products by type segment maintains a significant position throughout the forecast period.

Gluten-free pizzas and pastas accounts for a significant percentage of the gluten-free products market due to their popularity and versatility. These products will remain higher in demand because of the conveniences and the option for traditional Italian food without gluten that they afford to gluten-intolerant people and health-conscious consumers alike. This segment involves key players such as The Kraft Heinz Company (US), Conagra Brands, Inc. (US), and Silly Yaks – For Real Taste (Australia), providing a vast portfolio of gluten-free options. In March 2024, The Kraft Heinz Company (US) announced its version of gluten-free mac ‘n’ cheese under the brand name KD Gluten Free. This move caters to the rising demand for gluten-free alternatives while maintaining taste and quality to strengthen Kraft Heinz’s position in the market. These innovative pizzas and pastas drive significant growth, reflecting the segment’s robust consumer demand.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=738

In European region, Italy is poised to maintain its dominant position within the gluten-free products market throughout the forecast period.

Italy represents the highest market share in the gluten-free products market in the European region, owing to its high demand from consumers and strong market growth. Italy holds an important position due to its very strong tradition in bakery products, and adaptation to gluten-free alternatives by catering to the local demand and several million tourists. Some of the key players in the Italian market are Farmo S.p.A. (Italy), Dr. Schär AG / SPA (Italy), and Barilla G. e R. F.lli S.p.A (Italy), all headquartered in Italy. The companies hold important market shares in the gluten-free segment owing to their innovative products offered in the market and reaching the consumers due to an extensive distribution network. The various products that Farmo S.p.A offers are gluten-free bakery products, while Dr. Schär AG / SPA has a wide gluten-free portfolio of products, and Barilla also offers gluten-free pasta variants to suit wide consumer tastes. All these firms together give Italy an edge in the gluten-free market and grow the market hence meeting the rising demand for gluten-free products among consumers.

Top Gluten-free Products Companies

The key players in the market are The Kraft Heinz Company (US), The Hain Celestial Group (US), General Mills Inc. (US), Conagra Brands, Inc. (US), Kellanova (US), Barilla G. e R. F.lli S.p.A. (Italy), Raisio Oyj (Finland), Dr. Schär AG / SPA (Italy), Ecotone (France), Enjoy Life (US), Alara Wholefoods Ltd (England), Katz Gluten Free (US), Genius Food (UK), Silly Yaks – For Real Taste (Australia), and Norside Foods Ltd. (UK).

Gluten-free Products Industry News:

In July 2024, the flavors of Ore-Ida and GoodPop, brands of The Kraft Heinz Company, joined forces with frozen novelties in the creation of Fudge n’ Vanilla French Fry Pops, which is manufactured using vanilla oat milk, a chocolate fudge shell, crispy potato bits. With strategic placement into the gluten-free category, these two innovative, first-of-their-kind products were expected to place the companies in an excellent position to meet the increasing consumer demand for unique and allergen-friendly snacks.

In March 2024, Garden Veggie, The Hain Celestial Group’s brand, introduced Flavor Burst Tortilla Chips. These gluten-free tortilla chips were expected to be available in vegetable-infused flavors like Nacho Cheese and Zesty Ranch. This innovation is expected to help the company grow by providing consumers with healthy and nutritious gluten-free snacking options.

In February 2024, General Mills Inc.’s yogurt brand, Yoplait, also launched Yoplait Original with Chocolate Shavings in Cherry, Raspberry, and Strawberry flavors to add creaminess to this guilt-free treat of real chocolate. These gluten-free product offerings are expected to give the company a competitive edge in the market.

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=738

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gluten-Free Products Market Projected to Reach $11.48 Billion by 2029 | Key Players are The Kraft Heinz Company, The Hain Celestial Group, General Mills Inc., Conagra Brands, Inc., and Genius Food

Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Graves’ Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves’ Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Graves’ Disease Market by downloading the comprehensive report from DelveInsight @ Graves’ Disease Treatment Market Size

Key Takeaways from the Graves’ Disease Market Report

In September 2024:- Immunovant Sciences GmbH- A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED). To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
In September 2024:- Amgen- The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period. The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24.
As per DelveInsight’s estimates, Graves’ disease is the primary cause of hyperthyroidism, responsible for 60–80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves’ disease affects nearly 1 in 100 Americans.
According to Shang et al. (2024), an estimated 2.7–3.0% of the adult Chinese population—over 31 million individuals—are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
The leading Graves’ Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Gain a competitive edge in the Graves’ Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves’ Disease Treatment Drugs

Graves’ Disease Epidemiology Segmentation in the 7MM

Graves’ Disease Gender-specific Cases
Total Graves’ Disease Prevalent Cases
Graves’ Disease Age Group-specific Cases
Total Graves’ Disease Treated Cases

Graves’ Disease Market Insights

Graves’ disease, an autoimmune disorder and the leading cause of hyperthyroidism, characterized by symptoms such as weight loss, rapid heartbeat, and in some cases, thyroid eye disease. While traditional treatments like anti-thyroid medications, radioactive iodine therapy, and thyroidectomy remain the cornerstone of management. Anti-thyroid drugs, such as methimazole and propylthiouracil (PTU), are commonly used to suppress thyroid hormone production, with Methimazole being the preferred first-line therapy due to its efficacy and safety profile. Radioactive iodine therapy is favored in the United States, especially when drug therapy is ineffective or contraindicated. It induces hypothyroidism, requiring thyroid hormone replacement. However, it is not recommended for patients with Graves’ ophthalmopathy or smokers due to potential risks.

Discover key developments and opportunities in the Graves’ Disease Market. Click here to learn more from DelveInsight’s latest report @ Graves’ Disease Market Size

Graves’ Disease Treatment Market

The DelveInsight’s Graves’ Disease treatment market report gives a thorough understanding of Graves’ Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. The Graves’ Disease treatment market has experienced significant growth and evolution in recent years, reflecting the increasing prevalence of Graves’ disease, an autoimmune disorder that affects the thyroid gland. The Graves’ Disease treatment market has witnessed the advent of innovative treatment modalities, including anti-thyroid drugs, radioactive iodine therapy, and surgery

Graves’ Disease Companies and Therapies

Sling Therapeutics, Inc.: linsitinib
Immunovant Sciences GmbH: Batoclimab
Amgen: Teprotumumab
Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg
Hoffmann-La Roche: Satralizumab

Download DelveInsight’s Graves’ Disease Market report today and stay ahead in this rapidly evolving field. @ Graves’ Disease Clinical Trials

Scope of the Graves’ Disease Market Report

Coverage- 7MM
Graves’ Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
Graves’ Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement

Download the report to understand which factors are driving Graves’ Disease Market Trends @ Graves’ Disease Market Trends

Table of Content

1. Key Insights

2. Graves’ Disease Executive Summary

3. Competitive Intelligence Analysis for Graves’ Disease

4. Graves’ Disease: Market Overview at a Glance

5. Graves’ Disease: Disease Background and Overview

6. Patient Journey

7. Graves’ Disease Epidemiology and Patient Population

8. Graves’ Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Graves’ Disease Unmet Needs

10. Key Endpoints of Graves’ Disease Treatment

11. Graves’ Disease Marketed Products

12. Graves’ Disease Emerging Therapies

13. Graves’ Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Graves’ Disease Market Outlook

16. Graves’ Disease Market Access and Reimbursement Overview

17. Graves’ Disease KOL Views

18. Graves’ Disease Market Drivers

19. Graves’ Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion

The Key Schizophrenia Companies in the market include – Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.

DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast

Some of the key facts of the Schizophrenia Market Report:

The Schizophrenia market size was valued ~USD 7,972 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY™ (xanomeline and trospium chloride), an oral treatment for adult schizophrenia. COBENFY marks the first new class of medication in decades, offering a novel approach by specifically targeting M1 and M4 receptors in the brain, without blocking D2 receptors.
In May 2024, Teva and Medincell reported positive results from the Phase III SOLARIS trial, which evaluated the efficacy of TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injectable for adults with schizophrenia. SOLARIS is a multinational, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use in patients aged 18-65 with schizophrenia.
In March 2024, US-based biopharmaceutical company Acadia Pharmaceuticals announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for treating negative symptoms of schizophrenia failed to meet its primary endpoint. The 26-week, placebo-controlled trial enrolled 454 adult participants with negative symptoms of schizophrenia who had stable control of positive symptoms through ongoing antipsychotic therapy.
The US holds the largest market share for schizophrenia, valued at approximately USD 5,749 million, compared to the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
In 2022, Germany had the largest schizophrenia market size among the EU4 and the UK, at approximately USD 432 million. This market is expected to grow further, with Germany projected to maintain the largest share, followed by the UK, by 2034.
In 2022, Japan’s schizophrenia market was valued at approximately USD 676 million, making it the second largest market. This is expected to grow further by 2034.
According to DelveInsight’s analysis, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022, and this number is expected to rise throughout the study period (2020–2034).
DelveInsight’s analysis estimates that in 2022, the EU4 and the UK accounted for the largest share, approximately 42%, of the total diagnosed prevalent schizophrenia cases in the 7MM. These cases are expected to increase further by 2034.
DelveInsight analysts reported that in 2022, the gender-specific diagnosed prevalent cases of schizophrenia in the US were approximately 757,469 for males and 655,002 for females. These numbers are expected to fluctuate throughout the forecast period (2024-2034).
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
The Schizophrenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Individuals with schizophrenia may have difficulty distinguishing between what is real and what is imaginary, often experiencing delusions, hallucinations, disorganized thinking, and agitated body movements.

Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/schizophrenia-market

Schizophrenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Schizophrenia Epidemiology Segmentation:

The Schizophrenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Schizophrenia
Prevalent Cases of Schizophrenia by severity
Gender-specific Prevalence of Schizophrenia
Diagnosed Cases of Episodic and Chronic Schizophrenia

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast

Schizophrenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Schizophrenia Therapies and Key Companies

RP5063 (brilaroxazine): Reviva Pharmaceuticals
MIN-101 (roluperidone): Minerva Neurosciences
KarXT (xanomeline-trospium): Karuna Therapeutics
NUPLAZID (pimavanserin): Acadia Pharmaceuticals
ICELPERTIN (BI-425809): Boehringer Ingelheim
SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical
OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi
LYN-005: Lyndra Therapeutics
NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals
CVL-231 (emraclidine): Cerevel Therapeutics
Seroquel Sustained Release: AstraZeneca
Intramuscular Olanzapine Depot: Eli Lilly and Company
Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics
NBI-1117568: Neurocrine Biosciences

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

Schizophrenia Market Drivers

Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.

Schizophrenia Market Barriers

WHO’s Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.

Scope of the Schizophrenia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies
Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2020–2034)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17. Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion

Hydraulic Fluids Market Size, Emerging Trends, Development Status, and Business Opportunities & Top Key Players Analysis

“Browse 331 market data Tables and 58 Figures spread through 298 Pages and in-depth TOC on “Hydraulic Fluids Market”

The Hydraulic Fluids Market is experiencing steady growth, driven by increasing demand in industries such as construction, manufacturing, and automotive. Hydraulic fluids play a crucial role in machinery by transferring power efficiently while providing lubrication and reducing wear.

In terms of value, the hydraulic fluids market is estimated to grow from USD 8.7 billion in 2024 to USD 10.2 billion by 2029, at a CAGR of 3.2%. Hydraulic fluids market have grown as the demand from food processing end-use industry, and rising industrial growth in the Middle East & Africa and Asia Pacific region. These factors drive the hydraulic fluids market.

The key players profiled in the report include Shell plc (UK), Exxon Mobil Corporation (US), BP p.l.c. (UK), Chevron Corporation (US), TotalEnergies SE (France), FUCHS SE (Germany) PetroChina Company Limited (China), ENEOS Holdings, Inc. (Japan), China Petroleum & Chemical Corporation (China), Idemitsu Kosan Co., Ltd. (Japan), and others. The hydraulic fluids market has witnessed insignificant growth in the past few years; government regulations and changing lifestyle drive the growth of this market. Market players are introducing new technologies, acquisitions, collaborations and features to acquire larger market shares.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71021039

Shell plc is one of the world’s largest oil & gas companies. It operates its operations with their five business segments, namely, integrated gas, renewables & energy solutions, marketing, chemical & products, and upstream. The company offers its hydraulic fluids for a wide range of end-use industries including construction, power generation, food processing, cement manufacturing and among others. It operates with 6 base oil storage hubs, 10 grease plants, 32 blending plants, and 4 base oil manufacturing plants. It has strong presence in European, North American, South American, the Middle East & Africa, and Asia Pacific region. In January 2024, shell plc plc acquired the Environmentally Considerate Lubricants (ECLs) business from the PANOLIN Group, which has subsidiaries in Switzerland, the UK, the US, and Sweden.

Exxon Mobil Corporation is a global specialty oil & gas company and also one of the largest companies in standings of revenue generation. The company is a global leader for synthetic oil technology and markets its hydraulic fluids products globally with brands such as Exxon, Mobil, and Esso. It has strong presence globally in more than 160 countries. It operated with five business segments, energy products, upstream, chemical products, specialty products, and corporate & financing. The company owns 6 base stock refineries and 21 blending plants in 25 countries which are present in almost all regions. In May 2024, Exxon Mobil Corporation acquired Pioneer Natural Resources Company to establish a unique, unconventional business in the Permian Basin.

Get Sample Copy of this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71021039

Synthetic oil is estimated to be the largest base oil type of hydraulic fluids market, in terms of value, during the forecast period.

The second-largest base oil type for the hydraulic fluids is synthetic oil based lubricants due to better performance over the mineral oil in extreme applications. Moreover, their life span is longer than that of air-cooled types, they perform well within both high as well as low temperatures, and they perform a better duty to keep machinery safeguarded. Although they are slightly more expensive initially, their capacity to elongate service times and protect expensive parts within automobiles and aircrafts make them an economical decision for business within the automotive, aerospace, as well as industrial categories. Due to these reasons, they are popular and commonly used in various end-use industries due to their high performance and lower initial and maintenance costs in the long run. As such, the synthetic oil based lubricants established for steady growth based on the certain complex issues of market on one hand and total solution approach on the other hand with special focus on natural and sustainable lubricants.

Europe is estimated to be the second-largest market for the hydraulic fluids market, in terms of value, in 2023.

Europe is the second-largest consumer region for hydraulic fluids. Being home to highly developed industrial segments, Europe holds the second position in terms of the hydraulic fluids consumption. The area has a fairly large manufacturing sector, thus automotive, aerospace and machinery industries, and among others has always need good lubricants for the smooth running and durability of machinery. Also, it is necessary to mention that Europe gives high importance to environmental concerns and energy savings; therefore, today this region demands high-quality environment-friendly advanced lubricants.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=71021039

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hydraulic-fluid-market-71021039.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hydraulic Fluids Market Size, Emerging Trends, Development Status, and Business Opportunities & Top Key Players Analysis

BeamMed Inc. to Showcase Innovative Bone Density Scanner at NAACOS Fall 2024 Conference

“MiniOmni Portable Bone Density Scanner”

BeamMed Inc. is excited to announce its participation as an exhibitor at the NAACOS Fall 2024 Conference, held from October 16–18, 2024, at the prestigious Marriott Marquis in Washington, D.C. This premier event, organized exclusively by Accountable Care Organizations (ACOs), is a must-attend for healthcare professionals, offering two days of in-person sessions, pre-conference activities, and unparalleled networking opportunities.

NAACOS conferences are renowned for bringing together key stakeholders, including officials from the Centers for Medicare & Medicaid Services (CMS), ACO leaders, and policy insiders. This year’s fall event promises to provide invaluable insights into the future of healthcare delivery and policy, fostering collaboration among participants, speakers, and vendors.

At this pivotal event, BeamMed Inc. will be showcasing its innovative MiniOmni Portable Bone Density Scanner, a state-of-the-art solution designed to enhance patient care and operational efficiency. The MiniOmni is a fast, accurate, and portable bone density scanner that meets the criteria for HEDIS Osteoporosis Management in Women (OMW) and HEDIS Osteoporosis Screening in Older Women (OSW) measures. This cutting-edge technology offers healthcare providers a reliable tool for early detection and management of osteoporosis, thereby improving patient outcomes and reducing healthcare costs.

“We are thrilled to participate in the NAACOS Fall 2024 Conference,” said Gilad Zamir, VP of Sales at BeamMed Inc. “Our MiniOmni Portable Bone Density Scanner is designed to help healthcare providers deliver superior care with enhanced accuracy and efficiency. We look forward to connecting with ACO leaders and demonstrating how our technology can support their efforts in achieving better health outcomes for their patients.”

BeamMed Inc. invites all conference attendees to visit their exhibit booth to experience a live demonstration of the MiniOmni scanner and to learn more about its benefits in clinical practice. Attendees will have the opportunity to interact with BeamMed representatives, ask questions, and explore how this innovative technology can be integrated into their care models to enhance patient care quality and compliance with HEDIS measures.

For more information about BeamMed Inc. and the MiniOmni Portable Bone Density Scanner, please visit us at www.beammed.com

About BeamMed Inc.

BeamMed Inc. is a leading medical technology company dedicated to advancing bone health assessment solutions. With a commitment to innovation, accuracy, and portability, BeamMed Inc. has revolutionized bone density scanning, providing healthcare providers with state-of-the-art devices that enhance patient care and outcomes now, with rental options available.

Media Contact
Company Name: BeamMed Ltd.
Contact Person: Gilad Zamir
Email: Send Email
Phone: 800-769-6808
Address:950 S. Pine Island Road
City: Plantation
State: Florida
Country: United States
Website: www.beammed.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BeamMed Inc. to Showcase Innovative Bone Density Scanner at NAACOS Fall 2024 Conference

Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News

EMCORE Corporation (NASDAQ: EMKR) saw its shares soar today following a major announcement from Mobix Labs (NASDAQ: MOBX). Mobix Labs, a leader in advanced wireless solutions for military and defense, has submitted a proposal to acquire all outstanding shares of EMCORE for $3.80 per share in cash, positioning itself as a key player in the aerospace and defense sectors. This move could provide immediate value to shareholders, making it an attractive opportunity for those looking to capitalize on this offer. Read more.

In parallel, Peraso Inc. (NASDAQ: PRSO) has made significant strides with new strategic purchase orders, including deals with a Kenyan internet provider for its DUNE platform and a Korean contract to supply high-speed internet technology on trains. Additionally, Peraso secured a major military contract, further cementing its leadership in the 60 GHz mmWave technology market. Analysts at Benchmark have issued a “Buy” rating with a $4 price target, projecting strong growth fueled by its global expansion and military contracts. With a projected revenue surge in FY25, Peraso is a company investors should keep on their radar. Read entire report.

AGBA Group Holding Limited (NASDAQ: AGBA) also announced a pivotal moment in its growth trajectory with an amended merger agreement with Triller Corp. AGBA is expanding into high-growth social media and entertainment sectors through Triller’s AI-powered platform, unlocking new revenue channels such as pay-per-view and influencer sponsorships. This merger not only increases AGBA’s revenue potential but also positions it for significant global growth. For investors looking to capitalize on a diversified, tech-driven company with strong growth prospects, AGBA offers a timely investment opportunity.

CS Diagnostics Group (OTC: FZRO) has surged from its July 2024 low of $0.20 to close at $3.10 on September 27, 2024, after a landmark agreement to sell and transfer its CS Protect-Hydrogel assets, including patents, to CS Diagnostics Corp. The hydrogel, designed to protect healthy tissues during radiation therapy, received a valuation exceeding €960 million, supported by the precedent of a similar product acquired by Boston Scientific for $500 million in 2018. As part of the transaction, CS Diagnostics Corp. issued 110 million shares of common stock, equating to a $500 million payment—making this a stock to watch closely.

With EMCORE Corporation (NASDAQ: EMKR) poised for acquisition, Peraso Inc.’s (NASDAQ: PRSO) global expansion, AGBA Group’s (NASDAQ: AGBA) strategic merger with Triller and CS Diagnostics Group (OTC: FZRO) a stock to watch. These companies are positioned for strong growth and value creation. Now is the time for forward-thinking investors to take action and seize the opportunities presented by these market movers.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News